| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 570.1 | 484.7 | 425.2 |
| Other income | 5.2 | 8.5 | 4.4 |
| Total income | 575.3 | 493.2 | 429.6 |
| Profit before exceptional items & tax | 74.5 | 23.3 | 15.5 |
| Profit before tax | 74.5 | 23.3 | 15.5 |
| Net profit | 56.3 | 15.7 | 11.4 |
| Operating margin | 12.9% | 4.7% | 3.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +393.90% |
|---|---|
| Net profit, quarter on quarter | +258.60% |
| Revenue, year on year | +34.10% |
| Operating profit, year on year | +524.30% |
| Operating profit, quarter on quarter | +368.20% |
BSE results filing, NSE: MOREPENLAB. Figures extracted from the filing.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹120.38
- Market cap
- ₹6,596 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 46.9×Sector 50.4×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 1.46%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Annual General Meeting
Morepen Laboratories held its 41st Annual General Meeting on September 26, 2026, to conduct routine business, including dividend declaration and approval of director appointments.
Morepen Laboratories Other Announcement
Morepen Laboratories has been assigned an 'Adequate' ESG rating of 'CRISIL ESG 60' by Crisil ESG Ratings & Analytics Limited based on publicly disclosed information.
Morepen Laboratories Production Started
Morepen Laboratories successfully completed the first phase of its manufacturing capacity expansion. Installed reactor capacity for API and CDMO operations increased from 535 KL to 614 KL.
- reactor capacity increase
- 79.0 KL
Morepen Laboratories Annual General Meeting
Morepen Laboratories dispatched a notice to shareholders without registered emails providing the Annual Report 2025-26 weblink. The company proposed a final dividend of ₹0.20 per share.
Morepen Laboratories Annual General Meeting
Morepen Laboratories has scheduled its 41st Annual General Meeting for September 26, 2026. The board has proposed a final dividend of ₹0.20 per equity share.
- Value
- ₹197.1 Cr
Morepen Laboratories Bags ₹825 Cr Order from Leading global pharmaceutical company
Morepen Laboratories secured a multi-year CDMO mandate worth approximately ₹825 Crore from a global pharmaceutical firm. This represents one of the largest single mandates in the company's history.
- Value
- ₹825.0 Cr
- From
- Leading global pharmaceutical company
- Execution
- Multi-year